GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel.

Diabetes · 2012 · PMC3447900 · PMID 22855730

Europe PMC DOI

hedged sentences

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

borderline significantP = 0.053so close (0.05 < p ≤ 0.1)

29.2 ± 11.8) but was only borderline significant ( P = 0.053).

also in 11,409 other papers

failed to reach statistical significanceno p-value reported

233.9.1 ± 67.3 ng ⋅ min/mL (702.5 ± 202.1 ng ⋅ min/mL) for exendin-(9-39)] and in all dose-level time frames in the vehicle group compared with the exendin-(9-39) group but failed to reach statistical significance.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.